CUA 2017: Analysis of Real-World use of Radium-223 in Ontario

Toronto, Ontario ( Dr. Urban Emmenegger and colleagues presented their study assessing real-world utilization of the alpha emitter Radium-223 at the prostate cancer poster session at the 2017 CUA annual meeting. Based on the ALSYMPCA trial, we know that Radium-223 improves survival and delays skeletal related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) to the bone.1

CUA 2017: Adjuvant vs. Salvage Radiotherapy for Patients with Adverse Pathological Findings After Radical Prostatectomy: A Decision Analysis

Toronto, Ontario ( Dr. Christopher Wallis and colleagues presented results from their decision analysis for adjuvant vs salvage radiotherapy for patients with adverse pathological findings after radical prostatectomy at the prostate cancer poster session at the 2017 CUA annual meeting. Patients undergoing radical prostatectomy who have adverse pathological findings experience high rates of recurrence.

CUA 2017: Incidence and Predictors of Clinical Depression in Men with Prostate Cancer

Toronto, Ontario ( Dr. Robert Siemens and colleagues presented their results of incidence and predictors of clinical depression in men with prostate cancer at the prostate cancer poster session at the CUA 2017 annual meeting. Although depression in prostate cancer was previously linked only to men receiving androgen deprivation therapy (ADT), previous studies have demonstrated that up to 20% of men with prostate cancer report clinical depressive symptoms.1

CUA 2017: Statin Use and Time to Prostate Cancer Progression in Men Undergoing Active Surveillance

Toronto, Ontario ( At the prostate cancer poster session at the CUA 2017 annual meeting, Dr. Viranda Jayalath and colleagues presented their experience with statin use among men undergoing active surveillance (AS) for low-risk prostate cancer. Certainly, uptake rates of AS for appropriate men with low-risk prostate cancer are improving. Preclinical data support a protective effect of statins among patients with prostate cancer, however to date there is limited clinical data in the AS setting. The objective of this study was to provide a single center experience with statin use for men with prostate cancer on AS. 

CUA 2017: Early Cardiovascular Morbidity in a Pilot Prospective Randomized Trial Comparing Luteinizing Hormone-Releasing Hormone Agonist and Antagonist Among Patients with Advanced Prostate Cancer

Toronto, Ontario ( Dr. Jehonathan Pinthus from McMaster University and colleagues presented their results of cardiovascular morbidity in a pilot study comparing luteinizing hormone-releasing hormone (LHRH) agonist and LHRH antagonist use at the CUA 2017 prostate cancer poster session.

CUA 2017: Outcomes of Urothelial Bladder Cancer Patients who had Previous Upper Tract Urothelial Disease

Toronto, Ontario ( Urothelial carcinoma (UC) is often treated as one entity. However, more and more evidence is demonstrating that upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BCa) may be two distinct entities. As such, primary BCa and secondary BCa (following UTUC) may behave differently from one another. Studies show that secondary BCa or urothelial bladder carcinoma recurrence (UBCR) occurs in 22–47% of de novo UTUC (dNUTUC) patients.

CUA 2017: Predictors of Early Disease-Specific Mortality Among Patients with Prostate Adenocarcinoma and Bone Metastasis at Diagnosis

Toronto, Ontario ( Patients who present with metastatic prostate cancer represent an incurable subset of patients with prostate cancer. While management has traditionally been immediate initiation of androgen-deprivation therapy (ADT) alone, more recent studies have demonstrated evidence of concurrent administration of chemotherapy or androgen axis inhibitors (abiraterone).1,2,3,4

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.